|Day Low/High||113.29 / 115.52|
|52 Wk Low/High||101.36 / 132.13|
Company to add approximately 100 highly skilled jobs
INDIANAPOLIS, Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019.
- This analysis on effectiveness also shows Jardiance® (empagliflozin) was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov.
- EMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily Jardiance® (empagliflozin) in acute heart failure
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis
Based on these positive results, Lilly has submitted for U.S. regulatory approval for adults with active non-radiographic axial spondyloarthritis
Shares of the pharmaceutical company received a quant upgrade Monday.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CECO, DOC, FC, GLW, GNE, GORO, IVR, LLY, MR, NTB, NTR, PCYO, SENEB Downgrades: CLGX, HIMX, IRT, NCR, NGS, NMFC, PRTY, RLGY, TUSK Initiations: ARLO, GH, PRNB Read on to get TheStreet Quant Ratings' detailed report:
Thirty-one abstracts supporting Taltz® and Olumiant® highlight the latest innovative data in axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis
INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities.
INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities.
INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to...
INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13, 2019.
- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families - empagliflozin, linagliptin and insulin...
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
These stocks are priced for total imperfection. That's just what you want.
The most recent short interest data was recently released for the 04/15/2019 settlement date, and Lilly (Eli) & Co is the #102 most shorted of the S&P 500 components, based on 5.89 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Here's list of key companies to watch the week of October 21st.
INDIANAPOLIS, Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.
U.S. stock futures are mixed Wednesday and the global chip sector slumps following a revenue warning from Texas Instruments; Boeing, Caterpillar, Microsoft and Tesla to report earnings; Boeing's head of commercial airlines will leave the aerospace giant amid the 737 MAX crisis; Nike CEO Mark Parker to step down.
- Revenue in the third quarter of 2019 grew 3 percent, driven by 8 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, contributed 12 percentage points of revenue growth and represented approximately 44 percent of total revenue.
INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of...
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
INDIANAPOLIS, Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The late-stage trial of patients with metastatic pancreatic cancer 'did not meet its primary endpoint of overall survival,' Eli Lilly says.
INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with...
Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.